JO3183B1 - طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 - Google Patents

طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Info

Publication number
JO3183B1
JO3183B1 JOP/2011/0021A JOP20110021A JO3183B1 JO 3183 B1 JO3183 B1 JO 3183B1 JO P20110021 A JOP20110021 A JO P20110021A JO 3183 B1 JO3183 B1 JO 3183B1
Authority
JO
Jordan
Prior art keywords
dll4
methods
disorders
diseases
disease
Prior art date
Application number
JOP/2011/0021A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3183B1 publication Critical patent/JO3183B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي أساليب لعلاج مرض أو اضطراب، تكون فيه الزيادة في عدد خلايا (تريغ) T التنظيمية مفيدا، عن طريق إعطاء جرعة دوائية لمستهدف يعاني من ذلك المرض أو الاضطراب بجرعة علاجية من ضاد DII4 التي تقيد مسارات إشارة ثلمة-DII4، بذلك يزداد عدد خلايا تريغ. تشمل الأمراض أو الاضطرابات القابلة للعلاج عن طريق أساليب من هذا الاختراع مثل التصلب المتعدد (MS)، داء السكري، وما شابهها. يشمل الضاد المناسب DII4 لهذا الاختراع الأجسام المضادة أو جزيئات من الأجسام المضادة التي تربط بشكل خاص DII4 وتقيد تفاعلات ثلمة-DII4، والمجال الخارجي من DII4، وما شابهها. يوفر الاختراع أيضا أساليب لمنع حدوث أو عودة حدوث هكذا أمراض أو اضطرابات في مستهدف تعرض سابقا أو لديه قابلية للتعرض أو تطوير هكذا أمراض أو اضطرابات. علاوة على ذلك، فإن الأساليب من هذا الاختراع تكون مفيدة لمنع أو لعلاج رفض زراعة الأعضاء أو داء الطعم حيال الثوى.
JOP/2011/0021A 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 JO3183B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
JO3183B1 true JO3183B1 (ar) 2018-03-08

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Country Status (29)

Country Link
US (3) US8889133B2 (ar)
EP (2) EP2528945B1 (ar)
JP (2) JP5997613B2 (ar)
KR (2) KR101797918B1 (ar)
CN (2) CN102947336B (ar)
AR (1) AR080026A1 (ar)
AU (2) AU2011210771B2 (ar)
BR (2) BR112012018766A2 (ar)
CA (2) CA2787615C (ar)
CY (2) CY1118223T1 (ar)
DK (2) DK2528945T3 (ar)
ES (2) ES2605430T3 (ar)
HR (2) HRP20170130T1 (ar)
HU (2) HUE031432T2 (ar)
IL (2) IL220887A (ar)
JO (2) JO3183B1 (ar)
LT (2) LT2528945T (ar)
MX (2) MX343555B (ar)
MY (2) MY156538A (ar)
PL (2) PL2528946T3 (ar)
PT (2) PT2528945T (ar)
RS (2) RS55595B1 (ar)
RU (2) RU2587620C2 (ar)
SG (4) SG182527A1 (ar)
SI (2) SI2528945T1 (ar)
SM (2) SMT201600412B (ar)
TW (2) TWI564019B (ar)
UY (1) UY33206A (ar)
WO (2) WO2011094467A2 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
EP3680253A3 (en) 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201438736A (zh) * 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
CA2917402C (en) 2013-07-09 2019-10-22 Hanwha Chemical Corporation Novel dual-targeting protein binding specifically to dll4 and vegf and use thereof
CN111239415B (zh) * 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN106459971B (zh) * 2014-04-08 2019-08-16 弗劳恩霍夫应用研究促进协会 用于治疗自身免疫性疾病的联合疗法
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
EP3886856A4 (en) * 2018-11-29 2022-01-19 Zucco Sassi Yonezawa Siviglia, Debora METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER
US20240287173A1 (en) * 2021-03-30 2024-08-29 National University Corporation Kumamoto University Therapeutic agent for muscular atrophy
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20080107648A1 (en) * 2005-12-16 2008-05-08 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with DII4 antagonists
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
JP2009539384A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
BRPI0716424B8 (pt) * 2006-08-07 2021-05-25 Regeneron Pharma uso do antagonista de ligante delta-like 4 (dll4)
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3029070A1 (en) * 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
HUE031432T2 (en) 2017-07-28
HRP20170249T1 (hr) 2017-04-07
JP5883801B2 (ja) 2016-03-15
KR20130008017A (ko) 2013-01-21
HRP20170130T1 (hr) 2017-03-24
SG182527A1 (en) 2012-08-30
CA2787615A1 (en) 2011-08-04
BR112012018820A8 (pt) 2018-03-13
CN102947336B (zh) 2015-12-02
EP2528946B1 (en) 2016-11-16
SMT201600412B (it) 2017-01-10
US8765125B2 (en) 2014-07-01
RU2012136817A (ru) 2014-03-10
CA2787394A1 (en) 2011-08-04
KR101832118B1 (ko) 2018-02-26
EP2528945B1 (en) 2016-10-26
RS55715B1 (sr) 2017-07-31
US8889133B2 (en) 2014-11-18
JP5997613B2 (ja) 2016-09-28
IL220889A (en) 2017-07-31
UY33206A (es) 2011-08-31
MX2012008638A (es) 2012-12-05
MX343555B (es) 2016-11-10
RU2012136816A (ru) 2014-03-10
HUE032985T2 (en) 2017-11-28
MY156353A (en) 2016-02-15
JO3242B1 (ar) 2018-03-08
PT2528946T (pt) 2016-12-14
SG182528A1 (en) 2012-08-30
AU2011210771B2 (en) 2015-12-10
BR112012018766A2 (pt) 2017-01-10
PL2528946T3 (pl) 2017-04-28
TWI564019B (zh) 2017-01-01
SMT201700021B (it) 2017-03-08
AR080026A1 (es) 2012-03-07
CA2787394C (en) 2019-01-08
TW201615207A (zh) 2016-05-01
WO2011094467A3 (en) 2011-12-22
WO2011094465A1 (en) 2011-08-04
CA2787615C (en) 2019-01-15
AU2011210771A1 (en) 2012-08-23
KR20120123745A (ko) 2012-11-09
WO2011094465A4 (en) 2011-09-22
US20140255429A1 (en) 2014-09-11
IL220887A (en) 2017-07-31
EP2528946A1 (en) 2012-12-05
CN102884081A (zh) 2013-01-16
MX2012008740A (es) 2012-08-31
AU2011210773A1 (en) 2012-08-23
ES2609663T3 (es) 2017-04-21
PT2528945T (pt) 2016-12-14
IL220889A0 (en) 2012-09-24
RU2587624C2 (ru) 2016-06-20
ES2605430T3 (es) 2017-03-14
TW201136601A (en) 2011-11-01
TWI600433B (zh) 2017-10-01
LT2528945T (lt) 2017-01-25
SI2528946T1 (sl) 2017-01-31
PL2528945T3 (pl) 2017-02-28
RU2587620C2 (ru) 2016-06-20
CY1118223T1 (el) 2017-06-28
EP2528945A2 (en) 2012-12-05
SG10201500404QA (en) 2015-03-30
WO2011094467A2 (en) 2011-08-04
DK2528946T3 (en) 2017-02-20
BR112012018820A2 (pt) 2017-01-10
LT2528946T (lt) 2017-01-25
MY156538A (en) 2016-02-26
US20110189176A1 (en) 2011-08-04
JP2013518123A (ja) 2013-05-20
MX343553B (es) 2016-11-10
CY1118551T1 (el) 2017-07-12
JP2013518122A (ja) 2013-05-20
RS55595B1 (sr) 2017-06-30
CN102947336A (zh) 2013-02-27
KR101797918B1 (ko) 2017-11-15
AU2011210773B2 (en) 2015-11-19
SI2528945T1 (sl) 2017-01-31
DK2528945T3 (en) 2017-02-06
US20110189200A1 (en) 2011-08-04
SG10201500416RA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
UA115540C2 (uk) Антитіло до il-36r
PH12015501593A1 (en) Stable and soluble antibodies inhibiting vegf
TN2012000555A1 (en) Antibodies to human gdf8
MX2013008833A (es) Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX350355B (es) Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
EA201492149A8 (ru) St2-антигенсвязывающие белки
EA201391735A1 (ru) Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
WO2013067451A3 (en) Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2011004028A3 (en) Tlr3 binding agents
JO3097B1 (ar) الأجسام المضادة c-Met
MX360620B (es) Anticuerpos anti kit y usos de los mismos.
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
NZ609887A (en) Antibody against human prostaglandin e2 receptor ep4
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
EA201290977A1 (ru) Гуманизированные антитела к il-25
BR112014008331A2 (pt) anticorpos sema4a anti-humanos úteis para tratar doença
WO2012138102A3 (ko) Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
UA112521C2 (uk) Антитіло проти gdf8 людини
TN2011000001A1 (en) Compositions monovalent for cd28 binding and methods of use